AZ-LIMELIGHT-NETWORKS
Limelight Networks, Inc. (Nasdaq: LLNW ), a leading provider of content delivery network (CDN) and edge cloud services, has expanded its edge capabilities by launching EdgeFunctions, a new serverless compute service which allows developers to tap into the power of the company’s global network and gives them the flexibility to deploy and run their own code.
EdgeFunctions provides a customizable environment at the network edge for streamlining content workflows, performing time-sensitive decisions, and customizing user experiences. Providing this environment at the network edge offers Limelight’s low latency, on-demand scalability and high-performance network to developers. EdgeFunctions is ideal for streaming video and content delivery use cases such as personalized streaming, content protection, dynamic ad insertion, A/B testing, and image manipulation. Functions are globally available in Limelight’s highly distributed network and run closest to where content requests are received, ensuring Limelight’s lowest possible latency for code execution and optimal user experiences.
“We are thrilled to partner with Limelight to integrate our NexGuard Streaming forensic watermarking technology with EdgeFunctions and safeguard a premium OTT provider’s content from leaks and piracy,” said Jean-Philippe Plantevin, VP Anti-Piracy at NAGRA, a leading provider of content protection and multiscreen TV solutions. “Using EdgeFunctions, we were able to quickly deploy our customized solution into Limelight’s network edge locations and run them on demand, at scale, for both VOD and live OTT watermarking workflows.”
EdgeFunctions leverages Limelight’s global network to put flexibility and power directly into the hands of developers with support for several programming languages including Node.js, Python and Go. Its APIs enable these developers to manage, deploy and run their functions at the network edge and take advantage of Limelight’s direct peering connections with more than 1,000 ISPs and leading public cloud providers.
“Edge technology and solutions are rapidly expanding to meet a diverse set of customer needs. Limelight has an extensive global network with edge locations across the globe,” said Dave McCarthy, Research Director, Edge Strategies at IDC. “Giving developers more dynamic control over content combined with Limelight’s extensive global network optimizes the delivery of video at the edge.”
EdgeFunctions is Limelight’s latest innovation in the company’s edge compute solutions. These edge compute solutions now include serverless, virtual machine and bare metal solutions, providing edge compute capabilities how and where customers need them. In 2018 Limelight launched its first Edge Compute offering that allowed customers to access a highly connected environment that delivers low latency by combining globally distributed compute power with Limelight's high-performance network.
“We’ve evolved beyond high performing online video delivery with new innovative solutions to enhance online experiences and provide real value to our customers in ways that only we can. Now developers have the power to create and run bandwidth-intensive, latency-sensitive applications throughout our network edge,” said Bob Lento, CEO at Limelight. “Our extensive Edge Compute offering coupled with EdgeFunctions provides one of the most comprehensive content delivery and edge tool sets available today, and we have a robust development pipeline with much more to come. I’m thrilled to provide these services to the world’s leading companies.”
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW) is a global leader in delivering the highest quality online video experiences and edge-enabled workflows. Limelight has successfully helped launch and grow the largest video properties in the world and is on the forefront of enabling a new generation of applications that will disrupt markets and change our world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005739/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom